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Abstract: Gerstmann-Sträussler-Scheinker Disease (GSS) is a familial neurodegenerative disorder characterized 
clinically by ataxia, parkinsonism, and dementia, and neuropathologically by deposition of diffuse and amyloid 
plaques composed of prion protein (PrP). The purpose of this study was to evaluate if [11C]Pittsburgh Compound B 
(PiB) positron emission tomography (PET) is capable of detecting PrP-amyloid in PRNP gene carriers. Six individuals 
at risk for GSS and eight controls underwent [11C]PiB PET scans using standard methods. Approximately one year af-
ter the initial scan, each of the three asymptomatic carriers (two with PRNP P102L mutation, one with PRNP F198S 
mutation) underwent a second [11C]PiB PET scan. Three P102L carriers, one F198S carrier, and one non-carrier of 
the F198S mutation were cognitively normal, while one F198S carrier was cognitively impaired during the course 
of this study. No [11C]PiB uptake was observed in any subject at baseline or at follow-up. Neuropathologic study of 
the symptomatic individual revealed PrP-immunopositive plaques and tau-immunopositive neurofibrillary tangles in 
cerebral cortex, subcortical nuclei, and brainstem. PrP deposits were also numerous in the cerebellar cortex. This 
is the first study to investigate the ability of [11C]PiB PET to bind to PrP-amyloid in GSS F198S subjects. This finding 
suggests that [11C]PiB PET is not suitable for in vivo assessment of PrP-amyloid plaques in patients with GSS.
Keywords: [11C]Pittsburgh compound B (PiB) positron emission tomography (PET), Gerstmann-Sträussler-
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Introduction
Gerstmann-Sträussler-Scheinker disease (GSS) 
is an autosomal dominant neurodegenerative 
disorder associated with prion protein (PrP) 
gene (PRNP) mutations [1, 2]. Onset occurs 
most frequently between the fourth and the 
sixth decades of life, with an average disease 
duration of five years. GSS is clinically charac-
terized by ataxia, extrapyramidal signs, and 
cognitive impairment [3, 4]. The neuropatho-
logic diagnosis is based on the presence of uni-
centric and multicentric PrP-amyloid plaques in 
the cerebrum and cerebellum; however, the dis-
tribution and severity of PrP deposits vary sub-
stantially among GSS phenotypes [2]. 
In vivo imaging of amyloid has become a valu-
able tool for evaluating amyloid plaque burden. 
[11C]Pittsburgh compound B (PiB) is a positron 
emission tomography (PET) radioligand with a 
high affinity for beta-amyloid (Aβ) fibrils [5]. [11C]
PiB retention is strongly correlated with the 
presence of amyloid deposits made of Aβ pro-
tein in the post-mortem brain of patients with 
Alzheimer disease. Thus, [11C]PiB is capable of 
discriminating Alzheimer disease from non-
amyloidogenic neurodegenerative diseases [6, 
7]. [11C]PiB binds with high affinity to the β-sheet 
structure of Aβ plaques and fails to show reten-
tion with other abnormally conformed proteins 
such as tau of neurofibrillary tangles and 
α-synuclein of Lewy bodies [5, 7]. However, one 
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case study showed cerebellar [11C]PiB retention 
in a subject with BRI-amyloid (ABRI) deposition, 
suggesting that [11C]PiB may be capable of 
binding non-Aβ proteins found in plaques [8].
Like Aβ and ABRI, PrP-amyloid contains a high- 
er-order β-sheet secondary structure. Neuro- 
pathological dyes such as the Congo Red deriv-
ative (trans, trans),-1-bromo-2,5-bis-(3-hydroxy-
carbonyl-4-hydroxy) styrylbenzene (BSB) and 
the Thioflavin T derivative [4’-(methylamino)
phenyl] benzothiazole (BTA-1) bind these three 
types of amyloid, both in vitro and in vivo in 
mouse and human brains [9, 10]. Given that 
[11C]PiB is a Thioflavin T derivative, we hypoth-
esized that it may also bind to other amyloid 
proteins in addition to Aβ and ABRI. Previous 
[11C]PiB PET studies have demonstrated that 
[11C]PiB is not specifically retained in individu-
als affected by a prion disease; however, the 
majority of these reports were based on single 
case studies and a heterogeneous sample of 
prion diseases [11-15]. 
The purpose of this study was to evaluate if 
[11C]Pittsburgh Compound B (PiB) positron 
emission tomography (PET) is capable of 
detecting PrP-amyloid in PRNP mutation carri-
ers. We evaluated cross-sectional and longitu-
dinal [11C]PiB PET scans in asymptomatic carri-
ers of either the PRNP P102L or the PRNP 
F198S point mutations (proline to leucine at 
codon 102 (P102L) or phenylalanine to serine 
would provide evidence about the suitability of 
this tracer in trials of novel therapeutics or in 
early detection of PrP amyloidosis and differen-
tiating them from other prion disease. 
Materials and methods
Participants
Six participants at risk for GSS were included in 
this study. Three were PRNP P102L asymptom-
atic carriers (AC), one F198S non-carrier (NC), 
one F198S AC and one F198S symptomatic 
carrier (SC). Investigators were initially blinded 
to the participant’s genetic status related to the 
PRNP gene. Investigators were later unblinded 
after obtaining all neuropsychological and 
imaging data reported in the present paper. 
Neuropsychological testing, cognitive assess-
ments, and [11C]PiB PET imaging of one NC, four 
ACs, and one SC (Table 1) was completed at the 
Indiana Alzheimer Disease Center (IADC). In 
addition, neuropsychological, clinical, and [11C]
PiB PET data from eight cognitively healthy NCs 
from a separate study on aging and dementia 
at the IADC (the Indiana Memory and Aging 
Study (IMAS)) were included. All non-carriers 
and asymptomatic carriers displayed no clini-
cally relevant cognitive impairment or signifi-
cant cognitive complaints. The symptomatic 
carrier showed an initial onset of symptoms 
approximately 5-6 years prior to the [11C]PiB 
PET scan and was diagnosed with mild demen-
Table 1. Demographic characteristics and baseline neuropsychological 
and motor performance
NC (n = 9) AC (n = 4) SC (n = 1) p
Age 66.1 (4.2) 44.3 (11.7) 41 < 0.001
Gender (Male, Female) 3, 6 1, 3 0, 1 0.312
Education 16.7 (1.7) 14 (1.4) 13 < 0.001
Mutation Status (F198S, P102L) 0, 0 1, 3 1, 0 n.a.
MMSE* 28.9 (1.0)** 29.5 (0.6) 27 0.364
CDR-SB 0.1 (0.2) 0 (0.0) 6 0.933
COWA* 45.7 (8.0)*** 44 (6.1) 22 0.968
Finger Tapping (Dom) n.a. 49.5 (8.8) 26 n.a.
Finger Tapping (Non-Dom) n.a. 43.3 (8.8) 24 n.a.
Grooved Pegboard (Dom) n.a. 70.3 (8.1) 154 n.a.
Grooved Pegboard (Non-Dom) n.a. 80.3 (17.0) 149 n.a.
Mean (standard deviation). NC = non-carrier; AC = asymptomatic carrier; SC = symptomatic 
carrier; MMSE = Mini-Mental State Examination; CDR-SB = Clinical Dementia Rating-Sum of 
Boxes; COWA = Controlled Oral Word Association; n.a. = not available; Dom = dominant hand; 
Non-Dom = non-dominant hand). *Covaried for age, gender, and education; **Missing one 
non-carrier value; ***Missing three non-carrier values.
at codon 198 (F198S)) 
relative to non-carri-
ers. Furthermore, in 
a symptomatic GSS 
F198S patient, we 
investigated the neu-
ropathologic changes 
and correlated these 
findings with the [11C]
PiB PET data that was 
obtained 46 months 
prior to death. This is 
the first study to inves-
tigate the sensitivity 
of [11C]PiB PET for 
binding PrP-amyloid 
plaques in the F198S 
GSS mutation.
Determining the abili-
ty of [11C]PiB PET 
to detect PrP-amyloid 
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tia 2 years prior to the [11C]PiB PET scan. At the 
time of the scan, the symptomatic carrier pre-
sented with severe neurologic and motor 
impairments, as well as mild dementia (Table 
1). All participants or their legally authorized 
representative provided written informed con-
sent according to the Declaration of Helsinki 
and all procedures were approved by the 
Indiana University Institutional Review Board.
Genotyping 
Identification of point mutations in the PRNP 
gene was done as previously described [16]. 
Briefly, genomic DNA was isolated from fresh 
blood. The complete PRNP gene was amplified 
and direct sequencing performed using the 
DTCS quick start kit (Beckman Coulter, 
Fullerton, CA). The products were loaded onto a 
CEQ 8000 GeXP Genetic Analysis System 
(Beckman Coulter). DNA sequences were com-
pared with the published PRNP sequence 
(www.ncib.nlm.nih.gov).
Acquisition and assessment of [11C]PiB PET 
scans
All participants received a baseline [11C]PiB PET 
scan, acquired on a Siemens EXACT HR+ scan-
ner. Three asymptomatic carriers (2 PRNP 
P102L, 1 PRNP F198S) also received a second 
[11C]PiB PET scan approximately one year after 
the initial scan. Prior to each scan, a 10-minute 
transmission scan using three internal rod 
sources was acquired for attenuation correc-
tion. For the 6 individuals at risk for GSS (1 NC, 
4 AC, 1 SC), injection of [11C]PiB was followed by 
a 40 min uptake period. Dynamic data acquisi-
tion protocol was then initiated with the follow-
ing frame sequence: 6 × 5 min. Two partici-
pants from the IMAS study received a similar 
protocol as those at risk for GSS (40 min uptake 
period, dynamic acquisition, frame sequence: 
10 × 5 min). In the other 6 participants from 
IMAS (6 NC), data acquisition was initiated with 
the injection of [11C]PiB and the frame sequence 
was: 10 × 30 sec, 9 × 1 min, 2 × 3 min, 8 × 5 
min, 3 × 10 min. The average [11C]PiB injected 
across all participants (those at risk for GSS 
and IMAS) was 11.17±2.0 mCi. Scans were 
reconstructed using manufacturer’s software 
(Siemens; Knoxville, TN) for filtered back-pro-
jection. Corrections for scatter, randoms, and 
attenuation were applied.
Reconstructed [11C]PiB scans were processed 
using standard techniques. Using Statistical 
Parametric Mapping 8 (SPM8; Welcome De- 
partment of Cognitive Neuroscience, London, 
UK), scans were converted from ECAT to NiFTI 
format, coregistered to the structural magnetic 
resonance (MR) scan from the same visit (3T 
MPRAGE scan; Siemens Tim Trio), spatially 
aligned on a frame-by-frame basis, and normal-
ized to Montreal Neurologic Institute (MNI) 
space using matrices from segmentation of the 
same time-point MRI. A static [11C]PiB image 
from 40-70 minutes was created from the 
appropriate frames (depending on scan acqui-
sition type (see above)) and was intensity nor-
malized using a pons reference region to create 
a standardized uptake value ratio (SUVR) image 
for each participant. SUVR images were 
smoothed with an 8 mm FWHM Gaussian 
kernel. 
Visualization of the average group [11C]PiB 
images served as a primary qualitative assess-
ment. Mean baseline [11C]PiB SUVR images and 
mean normalized baseline structural MR imag-
es for each diagnostic/mutation status group 
were created using SPM8. To visualize [11C]PiB 
retention by group, mean [11C]PiB SUVR images 
were overlaid onto the respective group mean 
MR images in MRIcron (http://www.mccaus-
landcenter.sc.edu/mricro/mricron/). For each 
participant, mean [11C]PiB SUVR values were 
extracted from a global cortical grey matter 
(GM) region of interest (ROI) and a whole cere-
bellum ROI defined from the AAL atlas and 
extracted using MarsBaR [17]. SUVR values 
from each ROI were compared between diag-
nostic/mutation status groups as described 
below (Statistical Analysis). In the three AC sub-
jects with follow-up scans, the extracted mean 
[11C]PiB SUVR values from the ROIs at both 
time-points were graphed to complement quali-
tative visual observations.
Neuropathologic assessment
The symptomatic individual (PRNP F198S) 
expired 46 months after the [11C]PiB scan. 
Tissue was harvested at Indiana University 
School of Medicine. The fresh brain was hemi-
sected along the mid-sagittal plane. The left 
hemibrain was fixed in formalin and the right 
hemibrain was sliced, frozen, and stored at 
-70°C. 
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Following fixation in a 10% formalin solution, 
brain tissue samples were dehydrated in grad-
ed alcohols, cleared in xylene, and embedded 
in paraffin. Eight-micrometer-thick sections 
from multiple brain areas were stained with the 
histological and immunohistochemical meth-
ods described below. Hematoxylin and eosin 
(H&E) and luxol fast blue with hematoxylin & 
eosin (LFB-H&E) were used to survey gray and 
white matter for neuronal losses, gliosis, vascu-
lar pathology, and other possible pathologic 
lesions. Thioflavin S method was used to visual-
ize amyloid deposits and neurofibrillary tangles. 
Neurodegenerative pathology was analyzed 
using antibodies raised against amyloid β (Aβ) 
(21F12), tau (AT8), and PrP (3F4). 
The signal from polyclonal antibodies was visu-
alized using avidin-biotin, with goat anti-rabbit 
immunoglobulin as the secondary antibody, fol-
lowed by horseradish peroxidase-conjugated 
streptavidin and the chromogens diaminoben-
zidine or tetramethylbenzidine. The signal from 
monoclonal antibodies was detected using avi-
din-biotin, with goat anti-mouse immunoglobu-
lin as the secondary antibody, followed by alka-
line phosphatase-conjugated streptavidin and 
the chromogen diaminobenzidine or tetrameth-
ylbenzidine. Immunohistochemical sections 
were counterstained with hematoxylin. 
A semi-quantitative analysis of anatomical 
brain regions was carried out using a Leica 
DMLB microscope (Leica Wetzlar, Germany) 
from the following regions: superior frontal 
gyrus, middle frontal gyrus, anterior cingulate 
cortex, posterior cingulate cortex, superior and 
middle temporal gyri, superior parietal lobule, 
insular cortex, occipital cortex, amygdala, hip-
pocampus, subiculum, parahippocampus, cau-
date nucleus, putamen, globus pallidus, thala-
mus, cerebellar hemisphere, dentate nucleus, 
substantia nigra, locus coeruleus, basis pontis, 
and inferior olivary nucleus. The severity of neu-
ropathologic changes were evaluated using a 
subjective scale: none = 0, mild = 1 (+), moder-
ate = 2 (++), and severe = 3 (+++). 
Statistical analysis
Differences between NC and mutation carriers 
in continuous demographic variables and base-
line neuropsychological test performance were 
evaluated using an ANCOVA model. Differences 
in gender by diagnostic/mutation status were 
tested using a chi-square test. Age and years of 
education were used as covariates when evalu-
ating neuropsychological test scores. An 
ANCOVA model was also used to test for asso-
ciation of mutation status (carrier vs. non-carri-
er) with mean [11C]PiB SUVR values from the 
global cortical GM and cerebellar ROIs, covar-
ied for age and gender. All statistical analyses 
employed SPSS (version 22.0, Chicago, IL) and 
graphs were created with SigmaPlot (version 
10.0).
Results
The demographics, genetic status, and neuro-
psychological testing results at baseline are 
displayed in Table 1. Significant differences 
were observed for age and education between 
NC and mutation carriers. Although not statisti-
cally significant, more female than male partici-
pants were available for this study across all 
groups. As expected, the SC showed lower cog-
nition and significantly impaired manual motor 
performance compared to ACs and NCs. 
No apparent visual differences in baseline [11C]
PiB PET uptake were observed between the 
NCs, the ACs, and the SC individual, suggesting 
minimal [11C]PiB binding in ACs and even in the 
symptomatic individual (Figure 1A-C). MRI of 
the symptomatic carrier revealed a mild degree 
of atrophy of the cerebellar cortex. Quantitative 
regional analysis did not reveal any significant 
difference in [11C]PiB retention in either global 
cortical GM or cerebellum between mutation 
carriers (SC or ACs) and NCs (Figure 2D). 
Qualitative observation of the baseline and lon-
gitudinal follow-up scans for the 3 ACs did not 
show any appreciable increase in [11C]PiB sig-
nal over time (Figure 2A-C). This observation 
was supported by minimal longitudinal change 
in mean [11C]PiB SUVR in cortical GM and cere-
bellum ROIs (Figure 2D).
Moderate (++) to severe (+++) neuronal loss 
was observed in the superior frontal and cingu-
late gyri, putamen, caudate nucleus, superior 
and middle temporal gyri, hippocampus, subic-
ulum, entorhinal cortex, superior parietal lob-
ule, calcarine cortex, cerebellum, midbrain, and 
spinal cord (anterior horn cells; data not shown). 
In addition, moderate (++) axonal and myelin 
loss was observed in the superior frontal and 
cingulate gyri, caudate nucleus and putamen, 
superior parietal lobule, superior and inferior 
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Figure 1. Baseline [11C]PiB PET in F198S and P102L carriers and non-carriers. [11C]PiB SUVR images for (A) a symptomatic carrier, (B) asymptomatic carriers (n = 
4), and (C) non-carriers (n = 9). Note that (B and C) are the average image across participants within each group, while A is a single participant. No notable visual 
differences in [11C]PiB SUVR images were observed between the symptomatic carrier, asymptomatic carriers, and non-carriers. (D) [11C]PiB SUVR levels in the global 
cortical grey matter and the whole cerebellum in non-carriers and mutation carriers are displayed. No significant difference was observed in global cortex and whole 
cerebellum [11C]PiB SUVR between non-carriers and mutation carriers.
PiB PET in GSS
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Figure 2. Baseline [11C]PiB PET in F198S and P102L asymptomatic carriers. Baseline (left) and follow-up (right) [11C]PiB SUVR images for 3 asymptomatic carriers 
(2 P102L (A, B), 1 F198S (C)). No appreciable increase in [11C]PiB from the baseline to the follow-up scan was observed in any of the participants. (D) Quantitation 
of mean [11C]PiB SUVR in the cortical grey matter and whole cerebellum supported this qualitative observation.
PiB PET in GSS
90 Am J Nucl Med Mol Imaging 2016;6(1):84-93
temporal gyri, occipital lobe, cerebellar white 
matter, and spinal cord (dorsal spinocerebellar 
tract, anterior spinocerebellar tract, lateral cor-
ticospinal tract, posterior columns; data not 
shown). 
PrP (Figure 3A, 3C) and Thioflavin S positive 
(Figure 3E) unicentric and multicentric plaques 
(severe, +++) were observed in the superior 
frontal and cingulate gyri, putamen, caudate 
nucleus, superior and middle temporal gyri, hip-
pocampus, entorhinal cortex, superior parietal 
lobule, calcarine cortex, cerebellum, and 
midbrain. 
Tau-immunopositive neurofibrillary tangles 
(+++) (Figure 3B, 3D) and neuropil threads 
(+++) (Figure 3B, 3D) were observed in the 
superior frontal and cingulate gyri, entorhinal 
cortex, amygdala, substantia innominata, supe-
rior and middle temporal gyrus, thalamus, 
superior parietal lobule, middle frontal gyrus, 
posterior cingulate gyrus, precuneus, inferior 
parietal lobule, and substantia nigra. Figure 3 
is from frontal cortex but is representative of 
the cerebral cortex. PrP and tau pathologies 
were more prominent in the deeper layers of 
the cerebral cortex. In the cerebellum, there 
was a severe (+++) loss of neuronal perikarya 
which was associated with numerous (+++) 
PrP-immunopositive plaques. The white matter 
showed extensive (+++) axonal loss. Plaques 
were observed throughout all layers of the cer-
ebellar cortex (Figure 4A-C). No Aβ immunopos-
itive deposits were seen.
Discussion
[11C]PiB PET imaging is highly informative for 
the in vivo early detection of deposits of fibrillar 
Aβ and possibly for the differential diagnosis of 
Alzheimer disease versus other dementias. The 
aim of the present study was to determine the 
feasibility of using [11C]PiB PET to detect PrP-
amyloid deposits in individuals at risk for devel-
oping GSS, who are carriers of the PRNP P102L 
or F198S mutations. To our knowledge, this is 
the largest PET study investigating [11C]PiB in 
individuals at risk for GSS and the first to evalu-
ate [11C]PiB in GSS subjects with the F198S 
Figure 3. Extracellular PrP depos-
its and intracellular tau aggregates 
shown by immunohistochemistry 
and Thioflavin S in the frontal cor-
tex of the PRNP F198S carrier. 
3F4 immunohistochemistry reveals 
unicentric and multicentric PrP im-
munopositive plaques (A, C). AT8 
immunohistochemistry reveals tau-
immunopositive neurons and neuro-
pil threads (B, D). Plaques and neu-
rofibrillary tangles are fluorescent 
with Thioflavin S. PrP deposits and 
tau aggregates are shown at two dif-
ferent magnifications (A, B = 50 × 
total magnification and C-E = 100 × 
total magnification).
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mutation. Furthermore, this is the first study 
evaluating individuals at risk for a hereditary 
prion disease longitudinally using [11C]PiB PET. 
Our results show that there was no appreciable 
[11C]PiB retention in one symptomatic and four 
asymptomatic mutation carriers. Considering 
the fact that the asymptomatic mutation carri-
ers were close to the age of disease onset of 
their parents, it is conceivable that PrP-amyloid 
might have been already present in some of the 
AC individuals and particularly in the PRNP 
F198 symptomatic case. 
The findings in our sample are consistent with 
other reports that also show no [11C]PiB reten-
tion in participants with a PRNP mutation. Most 
of these studies investigated [11C]PiB PET in 
a single subject, with one study reporting a 
deposition. Further, in cases carrying the 
F198S mutation PrP-amyloid deposition begins 
prior to significant clinical symptoms (BG 
unpublished observations), suggesting that the 
older F198S AC in this study may also have had 
PrP-amyloid deposits that were not detected by 
[11C]PiB PET. In addition, in some cases Aβ is 
observed around the PrP-amyloid plaques [19, 
20]. However, we were unable to detect this in 
vivo using [11C]PiB PET despite its known sensi-
tivity for Aβ. MRI data of the SC obtained at the 
time of the [11C]PiB PET imaging (data not 
shown), revealed atrophy of the cerebellar cor-
tex, a finding supporting the view that extensive 
PrP amyloid deposits were already present 46 
months before death. Given the lack of appre-
ciable specific signal in the symptomatic GSS 
patient, we suggest that [11C]PiB may not bind 
Figure 4. Extracellular PrP deposits shown by immunohistochemistry and 
Thioflavin S in the cerebellum of the PRNP F198S carrier. 3F4 immunohis-
tochemistry reveals unicentric and multicentric PrP immunopositive plaques 
throughout the cerebellar cortex (A, C). Plaques are fluorescent with Thioflavin 
S (B). PrP deposits are shown at two different magnifications (A = 10 × to-
tal magnification and B = 100 × total magnification). Thioflavin S fluorescent 
plaques are shown at 100 × total magnification.
slightly larger sample size 
[11]. Our data extend these 
preliminary findings in a larg-
er cohort of participants. 
However, other studies have 
suggested that alternative 
amyloid tracers, including 
[18F]FDDNP and [11C]BF-227, 
show some sensitivity for 
GSS PrP-amyloid, opening up 
the possibility that the vari-
ous amyloid radioligands 
have unique binding proper-
ties with respect to amyloid 
type [15, 18]. 
The apparent lack of [11C]PiB 
retention was not likely due 
to an absence of PrP-amyloid 
in the PRNP mutation carri-
ers studied. No [11C]PiB re- 
tention was observed in the 
symptomatic individual, who 
had significant PrP-amyloid 
deposition in cortical and 
cerebellar regions, as shown 
in the neuropathologic speci-
men obtained 46 months 
after the PET study. The 
impairment in neuropsycho-
logical and motor perfor-
mance of this patient at the 
time of the PET scan also 
suggested a significant alter-
ation of cerebro-cortica, cer-
ebellar, and striatal function 
likely due to PrP-amyloid 
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to PrP-amyloid nor is there enough Aβ deposi-
tion to be detected by [11C]PiB PET. The appar-
ent lack of ability of [11C]PiB to detect PrP-
amyloid plaques in GSS could be due to several 
factors, including altered tracer distribution 
and metabolism in this sample. However, the 
most likely possibility is that the PrP-amyloid 
plaques possess a different conformational 
structure from the Aβ plaques, which may not 
be conducive to [11C]PiB binding despite their 
sensitivity to thioflavin on neuropathologic 
assessment. 
One limitation of this study is the small sample 
of symptomatic carriers who are known to have 
extensive neuropathological PrP-amyloid de- 
posits. Future studies using a larger sample of 
affected individuals would be desirable, as 
these participants would have significant 
amounts of the PrP-amyloid deposits. In addi-
tion, evaluation of other amyloid tracers alone 
or in combination with [11C]PiB may potentially 
provide valuable insight into the timing and dis-
tribution of PrP-amyloid deposition in this popu-
lation, as well as the relative sensitivity of dif-
ferent amyloid tracers for detection of the vari-
ous forms of amyloid. Finally, PET studies with 
recently developed tau radiotracers in individu-
als affected by GSS associated with the PRNP 
F198S, which are known to have neurofibrillary 
tangles, in combination with amyloid tracers 
could be useful for the in vivo analysis of patho-
physiological processes underlying disease 
symptoms and for tracking of disease 
progression. 
In summary, we found no evidence for signifi-
cant [11C]PiB retention in participants carrying 
the PRNP P102L or F198S mutations, regard-
less of diagnostic status. Our findings agree 
with previous reports and suggest that [11C]PiB 
may be clinically useful for ruling out the pres-
ence of Aβ plaques in people at risk for GSS, 
but would provide no utility for detecting PrP-
amyloid pathology in these patients.
Acknowledgements 
We would like to thank the GSS family members 
and IMAS participants for their participation in 
our research. We would also like to thank John 
D. West and Tamiko R. Magee for their assis-
tance with this project. This research was sup-
ported in part by grants from the National 
Institute on Aging (P30 AG10133 to BG and 
AJS; R01 AG19771, to AJS), the Alzheimer’s 
Association (to SLR), the Indiana University 
Health-Indiana University School of Medicine 
Strategic Research Initiative (to SLR), and the 
Indiana Clinical and Translational Science 
Institute (CTSI; to SLR).
Disclosure of conflict of interest
None.
Address correspondence to: Dr. Andrew J Saykin, 
Department of Radiology and Imaging Sciences, 
Indiana University School of Medicine, 355 W. 16th 
St., Suite 4100, Indianapolis, Indiana 46202, USA. 
Tel: +1 (317) 963-7501; Fax: +1 (317) 963-7547; 
E-mail: asaykin@iupui.edu; Dr. Bernardino Ghetti, 
Department of Pathology and Laboratory Medicine, 
Indiana University School of Medicine, 635 Barnhill 
Drive, Room A128, Indianapolis, Indiana 46202, 
USA. Tel: +1 (317) 274-7818; Fax: +1 (317) 274-
4882; E-mail: bghetti@iupui.edu
References
[1] Gerstmann J, Sträussler E and Scheinker I. 
Über eine eigenartige hereditär- familiäre Er-
krankung des Zentralnervensystems. Zugleich 
ein Beitrag zur Frage des vorzeitigen lokalen 
Alterns. Z Neur Psychiat 1936; 154: 736-762.
[2] Ghetti B, Tagliavini F, Takao M, Bugiani O and 
Piccardo P. Hereditary prion protein amyloido-
ses. Clin Lab Med 2003; 23: 65-85, viii.
[3] Farlow MR, Yee RD, Dlouhy SR, Conneally PM, 
Azzarelli B and Ghetti B. Gerstmann-Sträussler-
Scheinker disease. I. Extending the clinical 
spectrum. Neurology 1989; 39: 1446-1452.
[4] Unverzagt FW, Farlow MR, Norton J, Dlouhy SR, 
Young K and Ghetti B. Neuropsychological 
function in patients with Gerstmann-Sträussler- 
Scheinker disease from the Indiana kindred 
(F198S). J Int Neuropsychol Soc 1997; 3: 169-
178.
[5] Klunk WE, Engler H, Nordberg A, Wang Y, 
Blomqvist G, Holt DP, Bergstrom M, Savitcheva 
I, Huang GF, Estrada S, Ausen B, Debnath ML, 
Barletta J, Price JC, Sandell J, Lopresti BJ, Wall 
A, Koivisto P, Antoni G, Mathis CA and Lang-
strom B. Imaging brain amyloid in Alzheimer’s 
disease with Pittsburgh Compound-B. Ann 
Neurol 2004; 55: 306-319.
[6] Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, 
Mormino EC, Baker SL, Chetty S, Patel P, Pa-
gliaro TA, Klunk WE, Mathis CA, Rosen HJ, Mill-
er BL and Jagust WJ. 11C-PIB PET imaging in 
Alzheimer disease and frontotemporal lobar 
degeneration. Neurology 2007; 68: 1205-
1212.
PiB PET in GSS
93 Am J Nucl Med Mol Imaging 2016;6(1):84-93
[7] Ikonomovic MD, Klunk WE, Abrahamson EE, 
Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, 
Ziolko S, Bi W, Paljug WR, Debnath ML, Hope 
CE, Isanski BA, Hamilton RL and DeKosky ST. 
Post-mortem correlates of in vivo PiB-PET amy-
loid imaging in a typical case of Alzheimer’s 
disease. Brain 2008; 131: 1630-1645.
[8] Villemagne VL, Pike K, Pejoska S, Boyd A, Pow-
er M, Jones G, Masters CL and Rowe CC. 11C-
PiB PET ABri imaging in Worster-Drought syn-
drome (familial British dementia): a case 
report. J Alzheimers Dis 2010; 19: 423-428.
[9] Klunk WE, Wang Y, Huang GF, Debnath ML, 
Holt DP and Mathis CA. Uncharged thioflavin-T 
derivatives bind to amyloid-beta protein with 
high affinity and readily enter the brain. Life Sci 
2001; 69: 1471-1484.
[10] Ishikawa K, Doh-ura K, Kudo Y, Nishida N, Mu-
rakami-Kubo I, Ando Y, Sawada T and Iwaki T. 
Amyloid imaging probes are useful for detec-
tion of prion plaques and treatment of trans-
missible spongiform encephalopathies. J Gen 
Virol 2004; 85: 1785-1790.
[11] Boxer AL, Rabinovici GD, Kepe V, Goldman J, 
Furst AJ, Huang SC, Baker SL, O’Neil J P, Chui 
H, Geschwind MD, Small GW, Barrio JR, Jagust 
W and Miller BL. Amyloid imaging in distin-
guishing atypical prion disease from Alzheimer 
disease. Neurology 2007; 69: 283-290.
[12] Plate A, Benninghoff J, Jansen GH, Wlasich E, 
Eigenbrod S, Drzezga A, Jansen NL, 
Kretzschmar HA, Botzel K, Rujescu D and 
Danek A. Atypical parkinsonism due to a 
D202N Gerstmann-Straussler-Scheinker prion 
protein mutation: first in vivo diagnosed case. 
Mov Disord 2013; 28: 241-244.
[13] Villemagne VL, McLean CA, Reardon K, Boyd A, 
Lewis V, Klug G, Jones G, Baxendale D, Mas-
ters CL, Rowe CC and Collins SJ. 11C-PiB PET 
studies in typical sporadic Creutzfeldt-Jakob 
disease. J Neurol Neurosurg Psychiatry 2009; 
80: 998-1001.
[14] Hyare H, Ramlackhansingh A, Gelosa G, Edi-
son P, Rudge P, Brandner S, Brooks DJ, Collinge 
J and Mead S. 11C-PiB PET does not detect 
PrP-amyloid in prion disease patients including 
variant Creutzfeldt-Jakob disease. J Neurol 
Neurosurg Psychiatry 2012; 83: 340-341.
[15] Okamura N, Shiga Y, Furumoto S, Tashiro M, 
Tsuboi Y, Furukawa K, Yanai K, Iwata R, Arai H, 
Kudo Y, Itoyama Y and Doh-ura K. In vivo detec-
tion of prion amyloid plaques using [(11)C]BF-
227 PET. Eur J Nucl Med Mol Imaging 2010; 
37: 934-941.
[16] Hsiao K, Dlouhy SR, Farlow MR, Cass C, Da 
Costa M, Conneally PM, Hodes ME, Ghetti B 
and Prusiner SB. Mutant prion proteins in Ger-
stmann-Sträussler-Scheinker disease with 
neurofibrillary tangles. Nat Genet 1992; 1: 68-
71.
[17] Brett M, Anton JL, Valabregue R, Poline JB.  Re-
gion of interest analysis using an SPM toolbox 
[abstract]. In: Presented at the 8th Internation-
al Conference on Functional Mapping of the 
Human Brain, June 2-6, 2002: Sendai, Japan.
[18] Kepe V, Ghetti B, Farlow MR, Bresjanac M, 
Miller K, Huang SC, Wong KP, Murrell JR, Pic-
cardo P, Epperson F, Repovs G, Smid LM, Petric 
A, Siddarth P, Liu J, Satyamurthy N, Small GW 
and Barrio JR. PET of brain prion protein amy-
loid in Gerstmann-Straussler-Scheinker dis-
ease. Brain Pathol 2010; 20: 419-430.
[19] Miyazono M, Kitamoto T, Iwaki T and Tateishi J. 
Colocalization of prion protein and beta protein 
in the same amyloid plaques in patients with 
Gerstmann-Straussler syndrome. Acta Neuro-
pathol 1992; 83: 333-339.
[20] Bugiani O, Giaccone G, Verga L, Pollo B, Fran-
gione B, Farlow MR, Tagliavini F and Ghetti B. 
Beta PP participates in PrP-amyloid plaques of 
Gerstmann-Straussler-Scheinker disease, Indi-
ana kindred. J Neuropathol Exp Neurol 1993; 
52: 64-70.
